Two Democratic lawmakers are working to preserve health providers’ right to prescribe controlled substances via telehealth, including stimulants for ADHD and buprenorphine for opioid addiction.
A new bill being drafted by Sen. Mark Warner (D-Va.) and Rep. Doris Matsui (D-Calif.) comes months before the expiration of temporary waivers first enacted by the Drug Enforcement Administration’s during the Covid-19 pandemic. Though the DEA is currently contemplating new regulations that would roll back many of the pandemic-era flexibilities, the lawmakers’ new bill would likely extend the current rules through 2026, according to two lobbyists familiar with the effort.
The flexible rules are set to expire at the end of the year, which telehealth advocates say could threaten patient access to medications, including stimulants for ADHD and common medications used to treat opioid addiction.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
